Literature DB >> 6384027

Monoclonal anti-islet cell autoantibodies from C57BLKsJ db/db diabetic mice.

P Sai, C Maurel, M Kremer, P Barriere.   

Abstract

We have developed hybridomas producing anti-islet cell monoclonal autoantibodies (IC-MC auto Ab), by fusion of splenocytes from C57BLKsJ db/db diabetic mice with the SP2/O-Ag 14 myeloma. These IC-MC auto Ab were screened by an enzyme-linked immunosorbent assay, for their binding-ability to RINm5F insulinoma cells. Twenty IC-MC auto Ab were produced, which have differing immunoglobulin isotypes. Four of them induced a complement-dependent lysis of RINm5F cells in vitro, while the others did not. These two populations of auto Ab reflect the duality found in the intact db/db mouse. Immunoperoxidase procedures demonstrated that IC-MC auto Ab bound specifically to beta cell antigens of control pancreatic sections, in a similar pattern as auto Ab spontaneously "trapped" in the islets of db/db mice. Electron microscopic studies with an immunogold staining suggested that target antigens for IC-MC auto Ab were predominantly located in the cytoplasmic matrix of beta cells and, to a lesser extent, on their membranes. These antibodies represent powerful reactives for the studies concerning with the pathogeny of diabetes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6384027     DOI: 10.1089/hyb.1984.3.131

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  2 in total

1.  Monoclonal autoantibodies from insulin-dependent diabetic patients: autoantibodies against beta-cell surface or cytoplasmic antigens.

Authors:  E Houssaint; S Pogu; M Ouary; P Sai
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

2.  Pancreatic islet cell surface glycoproteins containing Gal beta 1-4GlcNAc-R identified by a cytotoxic monoclonal autoantibody.

Authors:  Y Uchigata; S L Spitalnik; O Tachiwaki; K F Salata; A L Notkins
Journal:  J Exp Med       Date:  1987-01-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.